This article needs additional citations for verification . Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  "Dermatologic and Ophthalmic Drugs Advisory Committee"  –  news · newspapers · books · scholar · JSTOR (April 2019) ( Learn how and when to remove this message )

The Dermatologic And Ophthalmic Drugs Advisory Committee (DODAC) receives requests for technical and clinical evaluation of new drugs by the U.S. Food and Drug Administration (FDA). The committee, consisting of members from academic and clinical dermatology, ophthalmology, biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat dermatologic and ophthalmic conditions.

References

External links

• Dermatologic And Ophthalmic Drugs Advisory Committee, official webpage:
• FDA Advisory Committees Calendar (including DODAC):

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e